HARVARD BIOSCIENCE INC cotiza a 8.24 USD y tiene una capitalización bursátil de $38M. En los últimos 12 meses ha facturado $88M con un margen de flujo de caja libre del 6.3%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-0.77 | — |
| Estimado | $-0.17 | $-0.21 | $-0.95 | $0.35 |
| Sorpresa | — | — | +18.9% | — |
| Métrica | HBIO | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 57.7% | 57.0% | +0.6% |
| Operating Margin | -56.1% | -38.6% | -17.5% |
| Net Margin | -65.5% | -33.6% | -32.0% |
| FCF Margin | 6.3% | -13.9% | +20.2% |
| ROE | -412.8% | -40.4% | -372.4% |
| ROA | -70.8% | -32.0% | -38.8% |
| Current Ratio | 2.20 | 2.84 | -0.64 |
| Debt / Equity | 2.61 | 0.28 | +2.33 |